topics

12/8/23

Abstract Interventional radiology employs image-guided techniques to perform minimally invasive procedures for diagnosis and treatment. Interventional radiology is often used to place central venous catheters and subcutaneous ports, with some evidence of benefit over surgical placement. Arterial embolization procedures are used to manage many types of hemorrhage and are highly effective for severe postpartum hemorrhage. Vascular interventions, such as endovascular treatment of varicosities, acute limb ischemia, and pulmonary embolism, are superior to surgical interventions. For chronic limb ischemia and deep venous thrombosis, the choice of therapy is not as clear. Inferior vena cava filters can be placed and removed endovascularly, but there is a significant risk of complications that increases over time. Vascular interventions can be effective for scrotal varicocele and uterine fibroids, although fibroid treatment is limited by high recurrence rates. Image-guided percutaneous drainage and biopsy have become standard of care. Interventional approaches are being used in oncology for local diagnosis and treatment. Percutaneous ablation and targeted delivery of chemotherapy and radiation therapy are being developed as alternatives when surgery is not practical. Vertebroplasty and kyphoplasty provide significant pain and functional improvement in patients with spinal metastases. PMID: 31038901 [PubMed - indexed for MEDLINE] 12:04 Video file Not included, change data exporting settings to download. 00:00, 2.7 KB 12:04 In reply to this message pubmed: caandvteortroorpul Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. //www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--media.wiley.com-assets-7388-64-JWS-SH-PubMed-BJCP-FREE.gif //www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.ncbi.nlm.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.png Related Articles Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol. 2019 02;85(2):422-431 Authors: Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M

Abstract

Interventional radiology employs image-guided techniques to perform minimally invasive procedures for diagnosis and treatment. Interventional radiology is often used to place central venous catheters and subcutaneous ports, with some evidence of benefit over surgical placement. Arterial embolization procedures are used to manage many types of hemorrhage and are highly effective for severe postpartum hemorrhage. Vascular interventions, such as endovascular treatment of varicosities, acute limb ischemia, and pulmonary embolism, are superior to surgical interventions. For chronic limb ischemia and deep venous thrombosis, the choice of therapy is not as clear. Inferior vena cava filters can be placed and removed endovascularly, but there is a significant risk of complications that increases over time. Vascular interventions can be effective for scrotal varicocele and uterine fibroids, although fibroid treatment is limited by high recurrence rates. Image-guided percutaneous drainage and biopsy have become standard of care. Interventional approaches are being used in oncology for local diagnosis and treatment. Percutaneous ablation and targeted delivery of chemotherapy and radiation therapy are being developed as alternatives when surgery is not practical. Vertebroplasty and kyphoplasty provide significant pain and functional improvement in patients with spinal metastases.

PMID: 31038901 [PubMed - indexed for MEDLINE]

12:04

Video file

Not included, change data exporting settings to download.

00:00, 2.7 KB

12:04

In reply to this message

pubmed: caandvteortroorpul

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--media.wiley.com-assets-7388-64-JWS-SH-PubMed-BJCP-FREE.gif //www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.ncbi.nlm.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.png Related Articles

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.

Br J Clin Pharmacol. 2019 02;85(2):422-431

Authors: Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M

. Interventional radiology is often used to place central venous catheters and subcutaneous ports, with some evidence of benefit over surgical placement. Arterial embolization procedures are used to manage many types of hemorrhage and are highly effective for severe postpartum hemorrhage. Vascular interventions, such as endovascular treatment of varicosities, acute limb ischemia, and pulmonary embolism, are superior to surgical interventions. For chronic limb ischemia and deep venous thrombosis, the choice of therapy is not as clear. Inferior vena cava filters can be placed and removed endovascularly, but there is a significant risk of complications that increases over time. Vascular interventions can be effective for scrotal varicocele and uterine fibroids, although fibroid treatment is limited by high recurrence rates. Image-guided percutaneous drainage and biopsy have become standard of care. Interventional approaches are being used in oncology for local diagnosis and treatment. Percutaneous ablation and targeted delivery of chemotherapy and radiation therapy are being developed as alternatives when surgery is not practical. Vertebroplasty and kyphoplasty provide significant pain and functional improvement in patients with spinal metastases.

PMID: 31038901 [PubMed - indexed for MEDLINE]

12:04

Video file

Not included, change data exporting settings to download.

00:00, 2.7 KB

12:04

In reply to this message

pubmed: caandvteortroorpul

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.

Br J Clin Pharmacol. 2019 02;85(2):422-431

Authors: Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M

BACKGROUND: The RIETE-VTE score was derived to risk-stratify patients with cancer-associated venous thromboembolism (CAT)

Abstract

BACKGROUND: The RIETE-VTE score was derived to risk-stratify patients with cancer-associated venous thromboembolism (CAT).

OBJECTIVES: To externally validate the RIETE-VTE score and to compare its prognostic performance with the modified Ottawa score.

PATIENTS/METHODS: We studied 178 elderly patients with CAT in a prospective multicenter cohort and assessed 30-day all-cause mortality, 90-day overall complications (mortality, major bleeding, or venous thromboembolism [VTE] recurrence), and 6-month VTE recurrence. Patients were stratified into RIETE-VTE and modified Ottawa score risk classes (low, intermediate, high). We compared the discriminative power (area under the receiver operating characteristics [ROC] curve) to predict mortality, overall complications, and VTE recurrence.

RESULTS: Fifteen patients (8.4%) died within 30 days, 42 (23.6%) experienced an overall complication by day 90, and 6 (3.4%) had recurrent VTE within 6 months. The RIETE-VTE and the modified Ottawa score classified similar proportions of patients as low-risk (35.4% vs 31.5%; P = .37). No low-risk patient died within 30 days. Low-risk patients identified by the RIETE-VTE and modified Ottawa score had similar rates of overall complications (7.9% vs 8.9%) and VTE recurrence (1.6% vs 1.8%). The modified Ottawa score and the RIETE-VTE score had similar areas under the ROC curve for predicting all-cause mortality (0.84 vs 0.75; P = .21), overall complications (0.74 vs 0.68; P = .26), and VTE recurrence (0.67 vs 0.64; P = .78).

CONCLUSIONS: Both the RIETE-VTE and modified Ottawa score accurately identified elderly patients with CAT who are at low-risk for short-term mortality and who are potential candidates for outpatient care.

PMID: 32124545 [PubMed - as supplied by publisher]

12:04

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:04

In reply to this message

pubmed: caandvteortroorpul

A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place.

J Neurol. 2020 Mar 02;:

Authors: Swan D, Seiffge DJ, Thachil J

The incidence and prevalence of patients who develop primary and secondary metastatic central nervous system cancer (CNS)

Abstract

The incidence and prevalence of patients who develop primary and secondary metastatic central nervous system cancer (CNS) is increasing. This is a consequence of advancements in the sensitivity and availability of diagnostic imaging, and improved therapeutic options, leading to increased detection of CNS malignancies and improved survival. These patients are at very high risk of thrombosis as well as haemorrhage, and the optimum management of anticoagulation can be challenging for treating clinicians, particularly as robust prospective evidence is sparse. In this focused review, we discuss (1) risk factors for thrombosis and bleeding in these patients, (2) management of acute venous thromboembolism (VTE) including evidence for direct oral anticoagulants, and how to approach patients with contraindications to anticoagulation, (3) ambulatory VTE prophylaxis, (4) VTE prophylaxis in patients who have undergone craniotomy for cancer, and (5) management of anticoagulation-related intracranial haemorrhage. Based on review of the available literature and author opinion, we propose practical management algorithms to aid clinicians faced with treating CNS cancer patients with thrombosis or CNS haemorrhage.

PMID: 32124043 [PubMed - as supplied by publisher]

12:04

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:04

In reply to this message

pubmed: caandvteortroorpul

Potential Mechanisms of Cancer-Related Hypercoagulability.

Cancers (Basel). 2020 Feb 29;12(3):

Authors: Nasser NJ, Fox J, Agbarya A

The association between cancer and thrombosis has been known for over a century and a half. However, the mechanisms

Abstract

The association between cancer and thrombosis has been known for over a century and a half. However, the mechanisms that underlie this correlation are not fully characterized. Hypercoagulability in cancer patients can be classified into two main categories: Type I and Type II. Type I occurs when the balance of endogenous heparin production and degradation is disturbed, with increased degradation of endogenous heparin by tumor-secreted heparanase. Type II hypercoagulability includes all the other etiologies, with factors related to the patient, the tumor, and/or the treatment. Patients with poor performance status are at higher risk of venous thromboembolism (VTE). Tumors can result in VTE through direct pressure on blood vessels, resulting in stasis. Several medications for cancer are correlated with a high risk of thrombosis. These include hormonal therapy (e.g., tamoxifen), chemotherapy (e.g., cisplatin, thalidomide and asparaginase), molecular targeted therapy (e.g., lenvatinib, osimertinib), and anti-angiogenesis monoclonal antibodies (e.g., bevacizumab and ramucirumab).

PMID: 32121387 [PubMed]

12:04

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:04

In reply to this message

pubmed: caandvteortroorpul

Randomized Controlled Study of an Absorbable Vena Cava Filter in a Porcine Model.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif Related Articles

Randomized Controlled Study of an Absorbable Vena Cava Filter in a Porcine Model.

J Vasc Interv Radiol. 2019 Sep;30(9):1487-1494.e4

Authors: Eggers M, Rousselle S, Urtz M, Albright R, Will A, Jourden B, Godshalk C, Dria S, Huang S, Steele J

AIMS: Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of

Abstract

AIMS: Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of cardiovascular magnetic resonance (CMR) in ICI-associated myocarditis. In this study, the CMR characteristics and the association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are presented.

METHODS AND RESULTS: From an international registry of patients with ICI-associated myocarditis, clinical, CMR, and histopathological findings were collected. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. In 103 patients diagnosed with ICI-associated myocarditis who had a CMR, the mean left ventricular ejection fraction (LVEF) was 50%, and 61% of patients had an LVEF ≥50%. Late gadolinium enhancement (LGE) was present in 48% overall, 55% of the reduced EF, and 43% of the preserved EF cohort. Elevated T2-weighted short tau inversion recovery (STIR) was present in 28% overall, 30% of the reduced EF, and 26% of the preserved EF cohort. The presence of LGE increased from 21.6%, when CMR was performed within 4 days of admission to 72.0% when CMR was performed on Day 4 of admission or later. Fifty-six patients had cardiac pathology. Late gadolinium enhancement was present in 35% of patients with pathological fibrosis and elevated T2-weighted STIR signal was present in 26% with a lymphocytic infiltration. Forty-one patients (40%) had MACE over a follow-up time of 5 months. The presence of LGE, LGE pattern, or elevated T2-weighted STIR were not associated with MACE.

CONCLUSION: These data suggest caution in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI-associated myocarditis.

PMID: 32112560 [PubMed - as supplied by publisher]

13:51

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:51

In reply to this message

pubmed: ctoall&ca or conall

Speckle tracking echocardiography in the early detection and prediction of anthracycline cardiotoxicity in diffuse large B-cell lymphoma treated with (R)-CHOP regimen.

Echocardiography. 2020 Feb 28;:

Authors: Wang B, Yu Y, Zhang Y, Hao X, Zhao H, Yang S, Sun Q, Wang Y

BACKGROUND: Despite speckle tracking echocardiography (STE) has emerged as a sensitive technique for identifying myocardial

Abstract

BACKGROUND: Despite speckle tracking echocardiography (STE) has emerged as a sensitive technique for identifying myocardial dysfunction, there are little data available on the appropriate timing to perform STE in the serial assessment after anthracycline administration. Moreover, further uncertainty is increased in the context of STE application in diffuse large B-cell lymphoma (DLBCL) research, as most recommendations are inferred by studies conducted primarily in breast cancer.

OBJECTIVE: This study aimed to determine whether early measurement of strain parameters derived by STE could predict the development of cardiotoxicity.

METHODS: Sixty-five patients were included in the final analysis. The patients were evaluated at baseline, after the third cycle and sixth-eighth cycle, and during follow-up. Global longitudinal strain (GLS) was analyzed using STE, and left ventricular ejection fraction (LVEF) was calculated by real time 3D echocardiography (RT3DE).

RESULTS: There was a significant decrease in GLS after the third cycle of chemotherapy and remained decreased during subsequent follow-up, whereas LVEF decreased only at follow-up. A percentage reduction in GLS of 13.8% between baseline and the third cycle of chemotherapy was the best predictor of further LVEF reduction.

CONCLUSION: Earlier monitoring timing and more accurate assessment methods might be helpful in the prevention of irreversible heart failure.

PMID: 32112477 [PubMed - as supplied by publisher]

3 March 2020

12:05

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:05

In reply to this message

pubmed: ctoall&ca or conall

Cardiac Magnetic Resonance T1 Mapping in Adolescent and Young Adult Survivors of Childhood Cancers.

Circ Cardiovasc Imaging. 2019 04;12(4):e008453

Authors: Tong X, Li VW, Liu AP, So EK, Chan Q, Ho KK, Yau JP, Cheuk DK, Cheung YF, Ng MY

PMID: 30929466 [PubMed - indexed for MEDLINE]

14:52

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

14:52

In reply to this message

pubmed: caandvteortroorpul

Treatment of venous thromboembolism in acute leukemia: A systematic review.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif Related Articles

Treatment of venous thromboembolism in acute leukemia: A systematic review.

Thromb Res. 2019 Jun;178:1-6

Authors: Ahrari A, Al-Ani F, Wang YP, Lazo-Langner A

BACKGROUND: The safety and efficacy of venous thromboembolism (VTE) treatment in patients with acute leukemia (AL) are not well

Abstract

BACKGROUND: The safety and efficacy of venous thromboembolism (VTE) treatment in patients with acute leukemia (AL) are not well understood and the optimal treatment strategy is unclear.

METHODS: We conducted a systematic review of the literature aiming to identify observational studies and randomized trials describing treatment of VTE in the setting of AL including, acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), and acute lymphoblastic leukemia (ALL). Due to the heterogeneity of findings, no meta-analysis was attempted.

RESULTS: A total of 13 observational studies (11 cohorts and 2 case-control) totaling 5359 participants were included. The number of patients with VTE among the total population was 304 (5.7%; 95% CI 5.1-6.3). In patients with VTE, 221 patients received treatment with anticoagulation using either of low-molecular-weight heparin, unfractionated heparin, and/or vitamin K antagonists. Most studies adjusted the anticoagulant dose based on platelet count. The reported recurrence rate ranged from 0 to 29% among different studies and varied according to the duration of anticoagulant treatment and follow up. Bleeding events were not uniformly reported but the total number was low among anti-coagulated patients.

CONCLUSION: There is a significant lack of data in this area with a high degree of heterogeneity in the choice of anticoagulant, dose adjustments for thrombocytopenia, and duration of anticoagulation. Further studies are required to develop guidelines and suggestions for treatment of VTE in AL.

PMID: 30921533 [PubMed - indexed for MEDLINE]

14:52

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

14:52

In reply to this message

pubmed: caandvteortroorpul

Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif Related Articles

Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis.

J Clin Anesth. 2019 Sep;56:41-42

Authors: Dibiasi C, Wiegele M, Gratz J

PMID: 30684925 [PubMed - indexed for MEDLINE]

14:52

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

14:52

In reply to this message

pubmed: caandvteortroorpul

The Challenge of Thromboprophylaxis in Cancer Patients-Balancing the Thrombotic and Bleeding Risks.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.thieme.de-classic-images-tc-logo_tc.jpg Related Articles

The Challenge of Thromboprophylaxis in Cancer Patients-Balancing the Thrombotic and Bleeding Risks.

Thromb Haemost. 2018 08;118(8):1347-1349

Authors: Potpara TS, Poposka L

PMID: 30060254 [PubMed - indexed for MEDLINE]

4 March 2020

12:04

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:04

In reply to this message

pubmed: caandvteortroorpul

Prognosis in patients with cancer-associated venous thromboembolism: Comparison of the RIETE-VTE and modified Ottawa score.

J Thromb Haemost. 2020 Mar 02;:

Authors: Pfaundler N, Limacher A, Stalder O, Méan M, Rodondi N, Baumgartner C, Aujesky D

BACKGROUND AND AIM: Disturbances of the enterohepatic circulation of bile acids (BAs) are seen in a number of clinically

Abstract

BACKGROUND AND AIM: Disturbances of the enterohepatic circulation of bile acids (BAs) are seen in a number of clinically important conditions, including metabolic disorders, hepatic impairment, diarrhea and gallstone disease. To facilitate the exploration of underlying pathogenic mechanisms, we developed a mathematical model built upon quantitative physiological observations across different organs.

METHODS: The model consists of a set of kinetic equations describing the syntheses of cholic, chenodeoxycholic and deoxycholic acids, as well as time-related changes of their respective free and conjugated forms in the systemic circulation, the hepato-portal region and the gastrointestinal tract. The core structure of the model was adapted from previous modeling research and updated based on recent mechanistic insights, including farnesoid X receptor (FXR)-mediated autoregulation of BA synthesis and selective transport mechanisms. The model was calibrated against existing data on BA distribution and feedback regulation.

RESULTS: According to model-based predictions, changes in intestinal motility, BA absorption and biotransformation rates differently affected BA composition and distribution: (1) inhibition of transintestinal BA flux (e.g., in patients with BA malabsorption) or acceleration of intestinal motility, followed by FXR downregulation, was associated with colonic BA accumulation; (2) in contrast, modulation of the colonic absorption process was predicted to not affect the BA pool significantly; (3) activation of ileal deconjugation (e.g., in patents with small intestinal bacterial overgrowth) was associated with an increase in the BA pool, due to higher ileal permeability of unconjugated BA species.

CONCLUSIONS: This model will be useful in further studying how BA enterohepatic circulation modulation may be exploited for therapeutic benefits.

PMID: 32112828 [PubMed - as supplied by publisher]

13:51

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:51

In reply to this message

pubmed: ctoall&ca or conall

Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.

Eur Heart J. 2020 Feb 29;:

Authors: Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zlotoff DA, Murphy SP, Stone JR, Golden DLA, Alvi RM, Rokicki A, Jones-O'Connor M, Cohen JV, Heinzerling LM, Mulligan C, Armanious M, Barac A, Forrestal BJ, Sullivan RJ, Kwong RY, Yang EH, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Coelho-Filho OR, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Mercurio V, Mahmoudi M, Lawrence DP, Reynolds KL, Weinsaft JW, Baksi AJ, Ederhy S, Groarke JD, Lyon AR, Fradley MG, Thavendiranathan P, Neilan TG

BACKGROUND/AIM: The aim of this study was to examine the efficacy and safety of direct oral anticoagulants for cancer-associated

Abstract

BACKGROUND/AIM: The aim of this study was to examine the efficacy and safety of direct oral anticoagulants for cancer-associated venous thromboembolism (VTE) in patients with active cancer.

PATIENTS AND METHODS: This study included patients with advanced unresectable/metastatic upper gastrointestinal (GI) or hepatopancreatobiliary (HPB) cancers with high risks of VTE and bleeding.

RESULTS: No significant differences were noted in potential bleeding factors between the rivaroxaban (n=105) and low-molecular-weight heparin (LMWH) (n=69) groups. Rivaroxaban exhibited similar risk of recurrent/aggravated VTE compared with LMWH (p=0.625) but increased risk of major bleeding (17.4% vs. 7.6%; p=0.072), clinically relevant bleeding (31.9% vs. 14.3%; p=0.019), and total bleeding (40.6% vs. 19%; p=0.010). The multivariate analysis regarded rivaroxaban as a significant factor for major bleeding (p=0.043) and clinically relevant bleeding (p=0.043).

CONCLUSION: Rivaroxaban exhibits comparable efficacy but increases bleeding risks compared with LMWH in patients with active unresectable/metastatic upper GI tract or HPB cancers, requiring extra caution of higher major bleeding risks.

PMID: 32111791 [PubMed - as supplied by publisher]

12:25

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:25

In reply to this message

pubmed: caandvteortroorpul

High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.

BMC Cancer. 2020 Feb 28;20(1):166

Authors: Fehr M, Hawle H, Hayoz S, Thuss-Patience P, Schacher S, Riera Knorrenschild J, Dürr D, Knoefel WT, Rumpold H, Bitzer M, Zweifel M, Samaras P, Mey U, Küng M, Winterhalder R, Eisterer W, Hess V, Gérard MA, Templeton A, Stahl M, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK), German Esophageal Cancer Study Group, Austrian Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), Fédération Francophone de Cancérologie Digestive (FFCD) / Fédération de Recherche en Chirurgie (FRENCH)

BACKGROUND: High rates of venous thromboembolic events (VTEs), mainly in advanced disease, are reported for patients

Abstract

BACKGROUND: High rates of venous thromboembolic events (VTEs), mainly in advanced disease, are reported for patients with cancer of the upper gastrointestinal tract (stomach, pancreas) and for treatment with cisplatin.

METHODS: Exploratory analysis of VTEs reported as adverse events and serious adverse events in a prospective, randomised, multicentre, multimodal phase III trial according to VTEs reported as adverse events and severe adverse events. Patients with resectable oesophageal cancer (T2N1-3, T3-4aNx) were randomized to 2 cycles of chemotherapy with docetaxel 75 mg/m2, cisplatin 75 mg/m2 followed by chemo-radiotherapy (CRT) and subsequent surgery (control arm) or the same treatment with addition of cetuximab (investigational arm).

RESULTS: VTEs occurred in 26 of 300 patients included in the trial, resulting in an incidence rate (IR) of 8.7% [95% CI 5.7-12.4%]. A total of 29 VTEs were reported:13 (45%) VTEs were grade 2, 13 (45%) grade 3 and three (10%) fatal grade 5 events. 72% (21/29) of all VTEs occurred preoperatively (IR 6.7%): 14% (4/29) during chemotherapy and 59% (17/29) during CRT. In multivariable logistic regression only adenocarcinoma (IR 11.1%, 21/189 patients) compared to squamous cell cancer (IR 4.5%, 5/111 patients) was significantly associated with VTE-risk during treatment, OR 2.9 [95%CI 1.0-8.4], p = 0.046. Baseline Khorana risk score was 0 in 73% (19/26), 1-2 in 23% (6/26) and 3 in only 4% (1/26) of patients with VTEs.

CONCLUSION: A high incidence of VTEs during preoperative therapy of resectable oesophageal cancer is observed in this analysis, especially in patients with adenocarcinoma. The role of prophylactic anticoagulation during neoadjuvant therapy in resectable esophageal cancer should be further evaluated in prospective clinical trials. According to our data, which are in line with other analysis of VTE-risk in patients with oesophageal cancer patients treated with neoadjuvant cisplatin-based chemotherapy and CRT, prophylactic anticoagluation could be considered balanced against individual bleeding risks, especially in patients with adenocarcinoma. In addition to the established risk factors, oesophageal adenocarcinoma treated with neoadjuvant cisplatin-based therapy may be regarded as a high-risk situation for VTEs.

TRIAL REGISTRATION: Registered at clinicaltrials.gov, NCT01107639, on 21 April 2010.

PMID: 32111181 [PubMed - as supplied by publisher]

13:51

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:51

In reply to this message

pubmed: ctoall&ca or conall

A physiology-based model of bile acid distribution and metabolism under healthy and pathological conditions in humans.

Cell Mol Gastroenterol Hepatol. 2020 Feb 26;:

Authors: Voronova V, Sokolov V, Al-Khaifi A, Straniero S, Kumar C, Peskov K, Helmlinger G, Rudling M, Angelin B

Platelets are most important to provide cellular hemostasis but also take part in inflammation and immune processes. Increased platelet

Abstract

Platelets are most important to provide cellular hemostasis but also take part in inflammation and immune processes. Increased platelet size has been regarded as a feature describing a young and more reactive subpopulation until studies were published which questioned this concept. Changes of platelet size given by the mean platelet volume (MPV) were described for immune thrombocytopenia, cardiovascular disease, atherosclerosis, venous thromboembolism, chronic lung disease, sepsis, cancer associated thrombosis, autoimmune disorders and others. This review summarizes the literature on what is known about platelets with different size and describes controversies of studies with large and small platelets putting a focus on their thrombogenicity and age in functional studies and on the association of MPV with the mentioned diseases.

PMID: 32108994 [PubMed - as supplied by publisher]

1 March 2020

12:25

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:25

In reply to this message

pubmed: caandvteortroorpul

INCREASED RISK OF SEVERE MATERNAL MORBIDITY AMONG INFERTILE WOMEN: ANALYSIS OF US CLAIMS DATA.

Am J Obstet Gynecol. 2020 Feb 26;:

Authors: Murugappan G, Li S, Lathi RB, Baker VL, Luke B, Eisenberg ML

BACKGROUND: Severe maternal morbidity continues to be an issue of national and global concern and is increasing in incidence.

Abstract

BACKGROUND: Severe maternal morbidity continues to be an issue of national and global concern and is increasing in incidence. The incidence of infertility is also on the rise, and infertile women experience a higher risk of incident chronic medical disease and cancer, suggesting that fertility may serve as a window to a woman's overall health.

OBJECTIVE: To investigate the risk of severe maternal morbidity by maternal fertility status.

STUDY DESIGN: Retrospective cohort analysis using Optum's de-identifed Clinformatics® Data Mart Database between 2003-2015. Infertile women stratified by infertility diagnosis, testing or treatment were compared to fertile women seeking routine gynecologic care. In both groups, only women who underwent pregnancy and delivery of a singleton during the follow up period were included. Main outcomes were severe maternal morbidity indicators, defined by the CDC, and identified by ICD-10 and CPT codes within 6 weeks of each delivery. Results were adjusted for maternal age, race, education, nulliparity, race, smoking, obesity, delivery mode, preterm birth, number of prenatal visits, and year of delivery.

RESULTS: 19,658 women comprised the infertile group and 525,695 women comprised the fertile group. The overall incidence of any severe maternal morbidity indicator was 7.0% among women receiving fertility treatment, 6.4% among women receiving a fertility diagnosis, 5.5% among women receiving fertility testing and 4.3% among fertile women.. Overall, infertile women had a significantly higher risk of developing any severe maternal morbidity indicator (AOR 1.22, CI 1.14-1.31, p<0.01)<0.01),<0.01),<0.01),<0.01),<0.01),<0.01),<0.01),<0.01)

CONCLUSION: Using an insurance claims database, we report that women diagnosed with infertility and women receiving fertility treatment experience a significantly higher risk of multiple indicators of severe maternal morbidity compared to fertile women. The increased risk of severe maternal morbidity noted among fertile Black women compared to fertile Caucasian women is attenuated among infertile Black women, who face similar risks as infertile Caucasian women.

PMID: 32112734 [PubMed - as supplied by publisher]

12:25

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:25

In reply to this message

pubmed: caandvteortroorpul

Rivaroxaban Versus Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer.

In Vivo. 2020 Mar-Apr;34(2):829-837

Authors: Kim JH, Seo S, Kim KP, Chang HM, Ryoo BY, Yoo C, Jeong JH, Lee JL, Im HS, Jeong H, Bang Y, Park SR

BACKGROUND: The National Comprehensive Cancer Network and American Society of Clinical Oncology recommend consideration of

Abstract

BACKGROUND: The National Comprehensive Cancer Network and American Society of Clinical Oncology recommend consideration of the use of echocardiography 6 to 12 months after completion of anthracycline-based chemotherapy in at-risk populations. Assessment of BNP (B-type natriuretic peptide) has also been suggested by the American College of Cardiology/American Heart Association/Heart Failure Society of America for the identification of Stage A (at risk) heart failure patients. The real-world frequency of the use of these tests in patients after receipt of anthracycline therapy, however, has not been studied previously.

METHODS AND RESULTS: In this retrospective study, using administrative claims data from the OptumLabs Data Warehouse, we identified 31 447 breast cancer and lymphoma patients (age ≥18 years) who were treated with an anthracycline in the United States between January 1, 2008 and January 31, 2018. Continuous medical and pharmacy coverage was required for at least 6 months before the initial anthracycline dose and 12 months after the final dose. Only 36.1% of patients had any type of cardiac surveillance (echocardiography, BNP, or cardiac imaging) in the year following completion of anthracycline therapy (29.7% echocardiography). Surveillance rate increased from 37.5% in 2008 to 42.7% in 2018 (25.6% in 2008 to 40.5% echocardiography in 2018). Lymphoma patients had a lower likelihood of any surveillance compared with patients with breast cancer (odds ratio, 0.79 [95% CI, 0.74-0.85]; P<0.001).<0.00150% rate of surveillance.

CONCLUSIONS: The majority of survivors of breast cancer and lymphoma who have received anthracycline-based chemotherapy do not undergo cardiac surveillance after treatment, including those with a history of cardiovascular comorbidities, such as heart failure.

PMID: 32106704 [PubMed - in process]

16:00

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

16:00

In reply to this message

pubmed: caandvteortroorpul

Use of GMI-1271, an E-selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis.

Res Pract Thromb Haemost. 2020 Feb;4(2):193-204

Authors: Devata S, Angelini DE, Blackburn S, Hawley A, Myers DD, Schaefer JK, Hemmer M, Magnani JL, Thackray HM, Wakefield TW, Sood SL

Background: There is an unmet need for antithrombotic treatments for venous thromboembolic disease that do not increase bleeding risk.

Abstract

Background: There is an unmet need for antithrombotic treatments for venous thromboembolic disease that do not increase bleeding risk. Selectins are cell adhesion molecules that augment thrombosis by activating immune cells to initiate the coagulation cascade. GMI-1271, a potent small-molecule E-selectin antagonist, has been shown in mouse models to decrease thrombus burden with a low risk of bleeding.

Methods: A first-in-human study of GMI-1271 was conducted to assess its safety, tolerability, and pharmacokinetic (PK) profile. As a secondary end point, biomarkers of coagulation, cell adhesion, and leukocyte/platelet activation were evaluated. Aims 1 and 2 were performed in healthy volunteers and evaluated single and multiple doses of the study drug, respectively. Aim 3 included 2 patients with isolated calf-level deep vein thrombosis (DVT).

Results: GMI-1271 showed consistent PK parameters for doses ranging from 2 to 40 mg/kg. Plasma levels increased in a linear manner with respect to dose, while clearance, volume of distribution, and half-life were not dose dependent. No accumulation was seen with multiple consecutive doses. No serious adverse events (grade 3 or 4) were reported. Biomarker analysis demonstrated a trend in reduction of soluble E-selectin (sEsel) levels with GMI-1271 exposure, while exposure did not impact laboratory testing of coagulation. Two patients with calf vein DVT were treated with GMI-1271 and demonstrated rapid improvement of symptoms after 48 hours, with repeat ultrasound showing signs of clot resolution.

Conclusions: We demonstrate that GMI-1271 is safe in healthy volunteers and provide proof of concept that an E-selectin antagonist is a potential therapeutic approach to treat venous thrombosis.

PMID: 32110749 [PubMed - as supplied by publisher]

16:00

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

16:00

In reply to this message

pubmed: caandvteortroorpul

Population-Based Analysis of Adherence to Post-Discharge Extended VTE Prophylaxis after Colorectal Resection.

Dis Colon Rectum. 2020 Feb 26;:

Authors: Mukkamala A, Montgomery JR, De Roo AC, Ogilvie JW, Regenbogen SE

BACKGROUND: Prevention of venous thromboembolism after colorectal surgery remains challenging. National guidelines

Abstract

BACKGROUND: Prevention of venous thromboembolism after colorectal surgery remains challenging. National guidelines endorse thromboembolism prophylaxis for 4 weeks after colorectal cancer resection. Expert consensus favors extended prophylaxis after inflammatory bowel disease surgery. Actual frequency of prescription after resection remains unknown.

OBJECTIVE: To assess prescription of extended, post-discharge venous thromboembolism prophylaxis after resection in Michigan.

DESIGN: Retrospective review of elective colorectal resections within a statewide collaborative receiving post-discharge, extended duration prophylaxis.

SETTING: This study was conducted between October 2015 and February 2018 at an academic center.

PATIENTS: A total of 5722 patients (2171 with colorectal cancer, 266 with inflammatory bowel disease, 3285 with other).

MAIN OUTCOME MEASURES: We compared prescription of extended, post-discharge prophylaxis over time, between hospitals, and by indication.

RESULTS: Of 5722 patients, 373 (6.5%) received extended duration prophylaxis after discharge. Use was similar between patients undergoing surgery for cancer (282/2171, 13.0%) or inflammatory bowel disease (31/266, 11.7%, p=0.54), but was significantly more common for both compared with patients with other indications (60/3285, 1.8%, p<0.001).<0.001))<0.05)300 beds) were significantly more likely to prescribe extended duration prophylaxis for all conditions (both p<0.001),

LIMITATIONS: This study was limited by lack of assessment of actual adherence, small number of observed venous thromboembolism events, small sample of inflammatory bowel disease patients, and restriction to state of Michigan.

CONCLUSIONS: Use of extended duration venous thromboembolism prophylaxis after discharge is increasing, but remains uncommon in most hospitals. Efforts to improve adherence may require quality implementation initiatives or targeted payment incentives. See Video Abstract at http://links.lww.com/DCR/B193.

PMID: 32109912 [PubMed - as supplied by publisher]

16:01

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

16:01

In reply to this message

pubmed: caandvteortroorpul

Large and small platelets - (when) do they differ?

J Thromb Haemost. 2020 Feb 28;:

Authors: Handtke S, Thiele T

Chemotherapy induces inevitable adverse effects, while complementary and alternative medicine employs many chemical substances

Abstract

Chemotherapy induces inevitable adverse effects, while complementary and alternative medicine employs many chemical substances. Herb pairs normally contain two herbal medicines, and they have satisfactory effects on cancer therapy. Zuojinwan, a well-known herb pair, is composed of Coptidis Rhizoma and Euodiae Fructus. Berberine and evodiamine are considered the most important compounds in the Zuojinwan herb pair. Previous reports have shown that combined use of evodiamine and berberine displays synergistic anticancer activities in various types of cancers, but this combination has not been tested in colorectal cancer. Hence, this study aimed to explore the combined effects of evodiamine and berberine on colorectal cancer cell lines and cardiomyocytes. We found that the combination of berberine and evodiamine showed synergistic anticancer activity in P-glycoprotein (P-gp)-positive colorectal cancer cells through attenuating the overexpression of P-gp mRNA independent of cell cycle arrest and cell apoptosis. However, berberine did not increase the cytotoxicity of evodiamine in normal human colon mucosal epithelial cells. Furthermore, berberine attenuated evodiamine-induced cardiotoxicity by regulating extrinsic apoptosis via nuclear factor erythroid-2-related factor 2 (Nrf2)-dependent and reactive oxygen species-independent pathways. Therefore, we suggest that the combination of berberine and evodiamine displays high anticancer activity while reducing the side effects in specific cell lines.

PMID: 32109457 [PubMed - as supplied by publisher]

13:21

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:21

In reply to this message

pubmed: ctoall&ca or conall

Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy.

Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e005984

Authors: Ruddy KJ, Sangaralingham LR, Van Houten H, Nowsheen S, Sandhu N, Moslehi J, Neuman H, Jemal A, Haddad TC, Blaes AH, Villarraga HR, Thompson C, Shah ND, Herrmann J

Background and Purpose: Even though new cancer therapies have improved the overall survival, in some cases they have been

Abstract

Background and Purpose: Even though new cancer therapies have improved the overall survival, in some cases they have been associated with adverse effects, including increased cardiotoxicity. The purpose of the present study was to assess the cardiovascular effects of adjuvant chemotherapy for colorectal cancer and mainly the impact on arterial stiffness indices.

Material and Methods: A total of 70 patients with non-metastatic colorectal cancer who were treated either with FOLFOX (n=16) or with XELOX (n=54) adjuvant chemotherapy were included in the study. All patients were subjected to full cardiovascular evaluation at the beginning and the end of chemotherapy. Arterial stiffness was assessed by means of pulse wave velocity (PWV) and augmentation index (Aix) and full laboratory examinations were conducted prior to, and soon after, the termination of chemotherapy.

Results: Patients exhibited significantly higher levels of carotid-radial PWV, carotid femoral RWV and Aix post-chemotherapy (p<0.001);

Conclusion: There is a clear burden in arterial stiffness indices post-adjuvant chemotherapy for colorectal cancer in both chemotherapy groups. This is a finding of important clinical significance, however more prospective studies are required in order to encode the possible mechanisms involved.

PMID: 32104097 [PubMed]

12:40

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:40

In reply to this message

pubmed: ctoall&ca or conall

February 2020 at a glance: acute heart failure and cardio-oncology.

Eur J Heart Fail. 2020 Feb;22(2):171-172

Authors: Adamo M, Lombardi CM, Metra M

PMID: 32103610 [PubMed - in process]

29 February 2020

13:21

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:21

In reply to this message

pubmed: ctoall&ca or conall

The Significance of Negative Lymph Nodes in Esophageal Cancer After Curative Resection: A Retrospective Cohort Study.

Cancer Manag Res. 2020;12:1269-1279

Authors: Mo J, Chen D, Li C, Chen M

Objective: The impact of negative lymph nodes (NLNs) count on prognosis in esophageal cancer (EC) was analyzed using two institutions surgical database.

Abstract

Objective: The impact of negative lymph nodes (NLNs) count on prognosis in esophageal cancer (EC) was analyzed using two institutions surgical database.

Methods: We conducted a retrospective study of 768 EC patients treated by surgical resection between January 2010 and December 2012. The effects of the NLNs count on prognosis was analyzed. Cox regression model was conducted to determine the significant prognostic elements.

Results: The number of NLNs was studied as a categorical variable based on the quartiles (Q1: ≤15, Q2: 16-21, Q3: 22-30, Q4: ≥31). And a better overall survival (OS) was observed with increasing number of NLNs (HR= 0.762; 95% CI, 0.596-0.974 for Q2, HR= 0.666; 95% CI, 0.516-0.860 for Q3 and HR= 0.588; 95% CI, 0.450-0.768 for Q4) (all P<0.05).

Conclusion: A higher number of NLNs is independently related to the better OS in EC patients after surgical resection.

PMID: 32110101 [PubMed - as supplied by publisher]

13:21

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:21

In reply to this message

pubmed: ctoall&ca or conall

Combined effects of berberine and evodiamine on colorectal cancer cells and cardiomyocytes in vitro.

Eur J Pharmacol. 2020 Feb 25;:173031

Authors: Guan X, Zheng X, Vong CT, Zhao J, Xiao J, Wang Y, Zhong Z

Abstract

OBJECTIVE: Painful bone metastases cause reduced quality of life (QoL) in patients with castration-resistant prostate cancer (CRPC). Alpha-emitter 223Radium is associated with a clear survival benefit and significant bone pain palliation in CRPC patients with symptomatic bone metastases. The aim of this study was to evaluate the association between pain relief and psychological distress during the time course of therapy in patients treated with 223Radium.

METHODS: A total of 63 patients with mCRPC undergoing 223Radium treatment in our Nuclear Medicine Unit, carefully instructed on the possibility of improving the pain and increasing the survival by the treatment, were retrospectively evaluated. Pain response during treatment was assessed with the Brief Pain Inventory Numeric Rating Scale. Psychological distress was evaluated through the analysis of specific items from EORTC QoL questionnaires C30 and BM22, submitted to patients at baseline and after each 223Radium cycle.

RESULTS: Pain intensity showed a significant decrease after first 223Radium administration (-1.03 points, p = 0.0032), with a subsequent stability through the course of treatment (-1.30 points, p = <0.001).

CONCLUSIONS: In our experience, bone pain palliation provided by 223Radium do not correlate with an improved psychological status in patients with advanced PC. This observation emphasises the role of the psychological aspect in the evaluation of the QoL and the necessity of a multidisciplinary approach in which the emotional aspect of the patient is carefully evaluated.

PMID: 31148330 [PubMed - indexed for MEDLINE]

28 February 2020

12:40

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:40

In reply to this message

pubmed: ctoall&ca or conall

Glycyrrhiza glabra (Licorice) root extract attenuates doxorubicin-induced cardiotoxicity via alleviating oxidative stress and stabilising the cardiac health in H9c2 cardiomyocytes.

J Ethnopharmacol. 2020 Feb 24;:112690

Authors: Upadhyay S, Mantha AK, Dhiman M

ETHNOPHARMACOLOGICAL RELEVANCE: Doxorubicin (DOX) is an effective anti-neoplastic drug, however; it has downside effects on cardiac

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Doxorubicin (DOX) is an effective anti-neoplastic drug, however; it has downside effects on cardiac health and other vital organs. The herbal remedies used in day to day life may have a beneficial effect without disturbing the health of the vital organs. Glycyrrhiza glabra L. is a ligneous perennial shrub belonging to Leguminosae/Fabaceae/Papilionaceae family growing in Mediterranean region and Asia and widespread in Turkey, Italy, Spain, Russia, Syria, Iran, China, India and Israel. Commonly known as mulaithi in north India, G. glabra has glycyrrhizin, glycyrrhetic acid, isoliquiritin, isoflavones, etc., which have been reported for several pharmacological activities such as anti-demulcent, anti-ulcer, anti-cancer, anti-inflammatory and anti-diabetic.

AIM OF THE STUDY: The objective of the present study is to investigate the interaction between the molecular factors like PPAR-α/γ and SIRT-1 during cardiac failure arbitrated by DOX under in vitro conditions and role of Glycyrrhiza glabra (Gg) root extract in alleviating these affects.

MATERIALS AND METHODS: In the present study, we have examined the DOX induced responses in H9c2 cardiomyocytes and investigated the role of phytochemical Glycyrrhiza glabra in modulating these affects. MTT assay was done to evaluate the cell viability, Reactive Oxygen Species (ROS)/Reactive Nitrogen Species (RNS) levels, mitochondrial ROS, mitochondrial membrane potential was estimated using fluorescent probes. The oxidative stress in terms of protein carbonylation, lipid peroxidation and DNA damage was detected via spectrophotometric methods and immune-fluorescence imaging. The cardiac markers and interaction between SIRT-1 and PPAR-α/γ was measured using Real-Time PCR, Western Blotting and Co-immunoprecipitation based studies.

RESULTS: The Glycyrrhiza glabra (Gg) extracts maintained the membrane integrity and improved the lipid homeostasis and stabilized cytoskeletal element actin. Gg phytoextracts attenuated aggravated ROS level, repaired the antioxidant status and consequently, assisted in repairing the DNA damage and mitochondrial function. Further, the expression of hypertrophic markers in the DOX treated cardiomyocytes reconciled the expression factors both at the transcriptional and translational levels after Gg treatment. SIRT-1 mediated pathway and its downstream activator PPAR factors are significant in maintaining the cellular functions. It was observed that the Gg extract allows regaining the nuclear SIRT-1 and PPAR-γ level which was otherwise reduced with DOX treatment in H9c2 cardiomyocytes. The co-immunoprecipitation (Co-IP) documented that SIRT-1 interacts with PPAR-α in the untreated control H9c2 cardiomyocytes whereas DOX treatment interferes and diminishes this interaction however the Gg treatment maintains this interaction. Knocking down SIRT-1 also downregulated expression of PPAR-α and PPAR-γ in DOX treated cells and Gg treatment was able to enhance the expression of PPAR-α and PPAR-γ in SIRT-1 knocked down cardiomyocytes.

CONCLUSIONS: The antioxidant property of Gg defend the cardiac cells against the DOX induced toxicity via; 1) reducing the oxidative stress, 2) maintaining the mitochondrial functions, 3) regulating lipid homeostasis and cardiac metabolism through SIRT-1 pathway and 4) conserving the cardiac hypertrophy and hence preserving the cardiomyocytes healt[...]

12:40

In reply to this message

h. Therefore, Gg can be recommended as a healthier supplement with DOX towards cancer therapeutics associated cardiotoxicity.

PMID: 32105749 [PubMed - as supplied by publisher]

12:40

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:40

In reply to this message

pubmed: ctoall&ca or conall

Cardiotoxic Profile and Arterial Stiffness of Adjuvant Chemotherapy for Colorectal Cancer.

Cancer Manag Res. 2020;12:1175-1185

Authors: Visvikis A, Kyvelou SM, Pietri P, Georgakopoulos C, Manousou K, Tousoulis D, Stefanadis C, Vlachopoulos C, Pektasides D

Abstract

OBJECTIVES: To compare variability of echocardiographic and cardiovascular magnetic resonance (CMR) measured left ventricular (LV) function parameters and their relationship to cancer therapeutics-related cardiac dysfunction (CTRCD).

METHODS: We prospectively recruited 60 participants (age: 49.8±11.6 years), 30 women with human epidermal growth factor receptor 2-positive breast cancer (15 with CTRCD and 15 without CTRCD) and 30 healthy volunteers. Patients were treated with anthracyclines and trastuzumab. Participants underwent three serial CMR (1.5T) and echocardiography studies at ~3-month intervals. Cine-CMR for LV ejection fraction (LVEF), myocardial tagging for global longitudinal strain (GLS) and global circumferential strain (GCS), two-dimensional (2D) echocardiography for strain and LVEF and three-dimensional (3D) echocardiography for LVEF measurements were obtained. Temporal, interobserver and intraobserver variability were calculated as the coefficient of variation and as the SE of the measurement (SEM). Minimal detected difference (MDD) was defined as 2xSEM.

RESULTS: Patients with CTRCD demonstrated larger mean temporal changes in all parameters compared with those without: 2D-LVEF: 4.6% versus 2.8%; 3D-LVEF: 5.2% vs 2.3%; CMR-LVEF: 6.6% versus 2.7%; 2D-GLS: 1.9% versus 0.7%, 2D-GCS: 2.5% versus 2.2%; CMR-GCS: 2.7% versus 1.6%; and CMR-GLS: 2.1% versus 1.4%, with overlap in 95% CI for 2D-LVEF, 2D-GCS, CMR-GLS and CMR-GCS. The respective mean temporal variability/MDD in healthy volunteers were 3.3%/6.5%, 1.8%/3.7%, 2.2%/4.4%, 0.8%/1.5%, 1.9%/3.7%, 1.8%/3.6% and 1.4%/2.8%. Although the mean temporal variability in healthy volunteers was lower than the mean temporal changes in CTRCD, at the individual level, 2D-GLS, 3D-LVEF and CMR-LVEF had the least overlap. 2D-GLS and CMR-LVEF had the lowest interobserver/intraobserver variabilities.

CONCLUSION: Temporal changes in 3D-LVEF, 2D-GLS and CMR LVEF in patients with CTRCD had the least overlap with the variability in healthy volunteers; however, 2D-GLS appears to be the most suitable for clinical application in individual patients.

PMID: 32098808 [PubMed - as supplied by publisher]

14:47

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

14:47

In reply to this message

pubmed: ctoall&ca or conall

No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--media.wiley.com-assets-7388-69-wiley-full-text.png Related Articles

No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium.

Eur J Cancer Care (Engl). 2019 Sep;28(5):e13112

Authors: De Vincentis G, Frantellizzi V, Follacchio GA, Farcomeni A, Pani A, Samaritani R, Schinzari G, Santini D, Cortesi E

Failure of remyelination underlies the progressive nature of demyelinating diseases such as multiple sclerosis. Macrophages and microglia are crucially

Abstract

Failure of remyelination underlies the progressive nature of demyelinating diseases such as multiple sclerosis. Macrophages and microglia are crucially involved in the formation and repair of demyelinated lesions. Here we show that myelin uptake temporarily skewed these phagocytes toward a disease-resolving phenotype, while sustained intracellular accumulation of myelin induced a lesion-promoting phenotype. This phenotypic shift was controlled by stearoyl-CoA desaturase-1 (SCD1), an enzyme responsible for the desaturation of saturated fatty acids. Monounsaturated fatty acids generated by SCD1 reduced the surface abundance of the cholesterol efflux transporter ABCA1, which in turn promoted lipid accumulation and induced an inflammatory phagocyte phenotype. Pharmacological inhibition or phagocyte-specific deficiency of Scd1 accelerated remyelination ex vivo and in vivo. These findings identify SCD1 as a novel therapeutic target to promote remyelination.

PMID: 32097464 [PubMed - as supplied by publisher]

12:43

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:43

In reply to this message

pubmed: ctoall&ca or conall

Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper.

Blood Adv. 2020 Feb 25;4(4):762-775

Authors: Neuendorff NR, Loh KP, Mims AS, Christofyllakis K, Soo WK, Bölükbasi B, Oñoro-Algar C, Hundley WG, Klepin HD

The incidence of acute myeloid leukemia (AML) increases with age. Intensive induction chemotherapy containing cytarabine and an anthracycline has b

Abstract

The incidence of acute myeloid leukemia (AML) increases with age. Intensive induction chemotherapy containing cytarabine and an anthracycline has been part of the upfront and salvage treatment of AML for decades. Anthracyclines are associated with a significant risk of cardiotoxicity (especially anthracycline-related left ventricular dysfunction [ARLVD]). In the older adult population, the higher prevalence of cardiac comorbidities and risk factors may further increase the risk of ARLVD. In this article of the Young International Society of Geriatric Oncology group, we review the prevalence of ARLVD in patients with AML and factors predisposing to ARLVD, focusing on older adults when possible. In addition, we review the assessment of cardiac function and management of ARLVD during and after treatment. It is worth noting that only a minority of clinical trials focus on alternative treatment strategies in patients with mildly declined left ventricular ejection fraction or at a high risk for ARLVD. The limited evidence for preventive strategies to ameliorate ARLVD and alternative strategies to anthracycline use in the setting of cardiac comorbidities are discussed. Based on extrapolation of findings from younger adults and nonrandomized trials, we recommend a comprehensive baseline evaluation of cardiac function by imaging, cardiac risk factors, and symptoms to risk stratify for ARLVD. Anthracyclines remain an appropriate choice for induction although careful risk-stratification based on cardiac disease, risk factors, and predicted chemotherapy-response are warranted. In case of declined left ventricular ejection fraction, alternative strategies should be considered.

PMID: 32097461 [PubMed - as supplied by publisher]

12:43

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:43

In reply to this message

pubmed: ctoall&ca or conall

Corrigendum to "The cardiotoxicity effect of different chemotherapeutic regimens in Iraqi patients with breast cancer: A follow up study" [Heliyon 5 (8) (August 2019) e02194].

Heliyon. 2020 Feb;6(2):e03398

Authors: Anber ZNH, Saleh BOM, Al-Rawi SA

Abstract

[This corrects the article DOI: 10.1016/j.heliyon.2019.e02194.].

PMID: 32095649 [PubMed - in process]

12:43

Video file

Not included, change data exporting settings to download.

00:00, 4.9 KB

12:43

In reply to this message

pubmed: ctoall&ca or conall

Early Detection and Monitoring of Cancer Chemotherapy-Related Left Ventricular Dysfunction by Imaging Methods.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo.gif //www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.ncbi.nlm.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.png Related Articles

Early Detection and Monitoring of Cancer Chemotherapy-Related Left Ventricular Dysfunction by Imaging Methods.

Arq Bras Cardiol. 2019 03;112(3):309-316

Authors: Ribeiro ML, Jorge AJL, Nacif MS, Martins WA

PMID: 30916206 [PubMed - indexed for MEDLINE]

27 February 2020

13:08

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:08

In reply to this message

pubmed: caandvteortroorpul

Lungenkarzinomchirurgie: hohes Thromboembolierisiko auch nach der Klinikentlassung.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.thieme.de-classic-images-tc-logo_tc.jpg Related Articles

Lungenkarzinomchirurgie: hohes Thromboembolierisiko auch nach der Klinikentlassung.

Zentralbl Chir. 2018 08;143(S 01):S7-S8

Authors:

PMID: 30184568 [PubMed - indexed for MEDLINE]

14:47

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

14:47

In reply to this message

pubmed: ctoall&ca or conall

Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity.

Heart. 2020 Feb 25;:

Authors: Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M, Fresno CU, Somerset E, Amir E, Marwick TH, Wintersperger BJ, Thavendiranathan P

BACKGROUND: Despite widespread acceptance of enhanced recovery after surgery protocols in other surgical specialties, plastic surgery has been

Abstract

BACKGROUND: Despite widespread acceptance of enhanced recovery after surgery protocols in other surgical specialties, plastic surgery has been slow to adopt fast-track principles. Recently, however, studies have shown that patients undergoing microsurgical breast reconstruction may benefit from a comprehensive postoperative protocol.

METHODS: All microsurgical breast reconstructions with abdominal free flaps performed by the senior author (A.K.) at a single institution from June 2009 to December 2013 were reviewed. Demographic information (e.g., age, body mass index, and comorbidities), operative details (e.g., laterality, type of flap), and postoperative data (e.g., complications, length of stay) were collected from patients' medical records. The authors employed a universal comprehensive protocol that dictated all postoperative care as it relates to diet, ambulation, flap monitoring, anticoagulation, analgesia, venous thromboembolism, antibiotic prophylaxis, and discharge criteria.

RESULTS: During the study period, 161 patients underwent 289 free flaps. The average length of stay for all patients was 3.26 ± 1.19 days. The incidence of complications requiring return to the operating room was 4.35% (7 patients). The incidence of flap failure was 0.69% (2 of 289 flaps). Only one flap failure occurred after hospital discharge. Statistical analysis demonstrated that the presence of any complication requiring return to the operating room increased hospital course by an average of 1.37 days (p = 0.0027).

CONCLUSION: The standardization of postoperative care for patients undergoing microsurgical breast reconstruction results in a short hospital length of stay without increasing the incidence of flap failure or postoperative complications requiring return to the operating room.

PMID: 31042802 [PubMed - indexed for MEDLINE]

14:58

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

14:58

In reply to this message

pubmed: ctoall&ca or conall

Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge.

J Oncol Pharm Pract. 2020 Feb 23;:1078155220904152

Authors: Lee DH, Armanious M, Huang J, Jeong D, Druta M, Fradley MG

PMID: 32089073 [PubMed - as supplied by publisher]

26 February 2020

12:43

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:43

In reply to this message

pubmed: ctoall&ca or conall

Stearoyl-CoA desaturase-1 impairs the reparative properties of macrophages and microglia in the brain.

J Exp Med. 2020 May 04;217(5):

Authors: Bogie JFJ, Grajchen E, Wouters E, Corrales AG, Dierckx T, Vanherle S, Mailleux J, Gervois P, Wolfs E, Dehairs J, Van Broeckhoven J, Bowman AP, Lambrichts I, Gustafsson JÅ, Remaley AT, Mulder M, Swinnen JV, Haidar M, Ellis SR, Ntambi JM, Zelcer N, Hendriks JJA

Background: The role for inferior vena cava (IVC) filters in the oncology population is poorly defined.

Abstract

Background: The role for inferior vena cava (IVC) filters in the oncology population is poorly defined.

Objectives: Our primary endpoint was to determine the rate of filter placement in cancer patients without an absolute contraindication to anticoagulation and the rate of recurrent VTE after filter placement in both retrievable and permanent filter groups. Patients/.

Methods: A single-institution, retrospective study of patients with active malignancies and acute VTE who received a retrievable or permanent IVC filter between 2009-2013. Demographics and outcomes were confirmed on independent chart review. Cost data were obtained using Current Procedural Terminology (CPT) codes.

Results: 179 patients with retrievable filters and 207 patients with permanent filters were included. Contraindication to anticoagulation was the most cited reason for filter placement; however, only 76% of patients with retrievable filters and 69% of patients with permanent filters had an absolute contraindication to anticoagulation. 20% of patients with retrievable filters and 24% of patients with permanent filters had recurrent VTE. The median time from filter placement to death was 8.9 and 3.2 months in the retrievable and permanent filter groups, respectively. The total cost of retrievable filters and permanent filters was $2,883,389 and $3,722,688, respectively.

Conclusions: The role for IVC filters in cancer patients remains unclear as recurrent VTE is common and time from filter placement to death is short. Filter placement is costly and has a clinically significant complication rate, especially for retrievable filters. More data from prospective, randomized trials are needed to determine the utility of IVC filters in cancer patients.

PMID: 32089887 [PubMed]

13:17

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:17

In reply to this message

pubmed: caandvteortroorpul

Simple hepatic cyst rupture exacerbated by anticoagulation.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-bmjjournals_full.gif Related Articles

Simple hepatic cyst rupture exacerbated by anticoagulation.

BMJ Case Rep. 2019 Sep 16;12(9):

Authors: Tong KS, Hassan R, Gan J, Warsi A

Simple hepatic cysts are usually asymptomatic but can rarely result in life-threatening complications such as haemoperitoneum secondary

Abstract

Simple hepatic cysts are usually asymptomatic but can rarely result in life-threatening complications such as haemoperitoneum secondary to rupture. A 70-year-old woman with known simple hepatic cyst presented with acute chest pain and dyspnoea. The initial diagnosis was pulmonary embolism, and anticoagulation was commenced. However, she subsequently collapsed with haemodynamic instability. CT revealed a large hepatic cyst haematoma with rupture into the peritoneal cavity. The patient underwent emergency laparotomy, haemostasis and partial deroofing of the cyst. Retrospective review of CT scans suggested that the bleed had begun on presentation but was exacerbated by anticoagulation. To our knowledge, this is the first report of haemorrhagic hepatic cyst associated with acute anticoagulation. We discuss several important clinical lessons including cyst rupture as a possible cause of chest pain, the need for careful review of imaging and the choice of anticoagulation in patients with known simple hepatic cyst.

PMID: 31527205 [PubMed - indexed for MEDLINE]

13:17

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:17

In reply to this message

pubmed: caandvteortroorpul

Reducing Length of Stay after Microsurgical Breast Reconstruction with a Standardized Postoperative Protocol.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.thieme.de-classic-images-tc-logo_tc.jpg Related Articles

Reducing Length of Stay after Microsurgical Breast Reconstruction with a Standardized Postoperative Protocol.

J Reconstr Microsurg. 2019 Oct;35(8):557-567

Authors: DelMauro MA, Chen K, Keller A

Cerebral air embolism combined with cardiomyopathy secondary to pulmonary barotrauma is rare. Here, we report an unusual case

Abstract

Cerebral air embolism combined with cardiomyopathy secondary to pulmonary barotrauma is rare. Here, we report an unusual case of cerebral air embolism combined with transient cardiomyopathy secondary to large bulla rupture during a pulmonary function test after lung cancer surgery. The patient experienced loss of consciousness. Computed tomography and magnetic resonance imaging suggested a cerebral air embolism. Electrocardiography showed ST-segment elevation and abnormally high plasma levels of cardiac enzymes. Echocardiography and coronary angiography suggested cardiomyopathy. The patient was discharged with no sequelae.

PMID: 32090056 [PubMed]

13:16

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:16

In reply to this message

pubmed: caandvteortroorpul

Safety and Outcomes of Permanent and Retrievable Inferior Vena Cava Filters in the Oncology Population.

Int J Vasc Med. 2020;2020:6582742

Authors: Shaikh SS, Kamath SD, Ghosh D, Lewandowski RJ, McMahon BJ

OBJECTIVE: To investigate the effectiveness of a home-based preoperative rehabilitation program for improving preoperative lung function and surgical

Abstract

OBJECTIVE: To investigate the effectiveness of a home-based preoperative rehabilitation program for improving preoperative lung function and surgical outcome of patients with chronic obstructive pulmonary disease (COPD) undergoing lobectomy for cancer.

METHODS: This was a prospective, observational, single-center study including 59 patients with mild COPD who underwent lobectomy for lung cancer. All patients attended a home-based preoperative rehabilitation program including a minimum of 3 sessions each week for 4 weeks. Each session included aerobic and anaerobic exercises. Participants recorded the frequency and the duration of exercise performed in a diary. The primary end point was to evaluate changes in lung function including predicted postoperative (PPO) forced expiratory volume in 1 second (FEV1), 6-minute walking distance test (6MWD), PPO diffusing capacity for carbon monoxide (DLCO) %, and blood gas analysis values before and after the rehabilitation program. Postoperative pulmonary complications were recorded and multivariable analysis was used to identify independent prognostic factors (secondary end point).

RESULTS: All patients completed the 4-week rehabilitation program. Thirteen of 59 (22%) patients (Group A) performed <3

CONCLUSIONS: Our simple and low-cost rehabilitation program could improve preoperative clinical function in patients with mild to moderate COPD undergoing lobectomy and reduce postoperative pulmonary complications. All patients should be motivated to complete at least 3 rehabilitation sessions per week in order to obtain significant clinical benefits. Our preliminary results should be confirmed by larger prospective studies.

PMID: 32090715 [PubMed - as supplied by publisher]

13:16

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:16

In reply to this message

pubmed: caandvteortroorpul

Cerebral Air Embolism and Cardiomyopathy Secondary to Large Bulla Rupture during a Pulmonary Function Test.

Korean J Thorac Cardiovasc Surg. 2020 Feb;53(1):34-37

Authors: Lee H, Lee HS, Moon DH, Lee S

BACKGROUND: Sarcopenia has been implicated as a positive predictor of postsurgical complications. Its role in head and neck (H&N

Abstract

BACKGROUND: Sarcopenia has been implicated as a positive predictor of postsurgical complications. Its role in head and neck (H&N) free flap reconstruction has yet to be examined. Our study aimed to determine the clinical impact of sarcopenia on postoperative outcomes in patients receiving autologous free tissue reconstruction for H&N cancer (HNC).

METHODS: A retrospective case-control study was conducted at our tertiary referral center. Patients with HNC who received oncologic resection followed by autologous free tissue reconstruction were included. Preoperative abdominal computed tomography (CT) imaging was analyzed at the third lumbar vertebra (L3) to calculate skeletal muscle cross-sectional area (CSA, cm2). Skeletal muscle index (SMI, cm2/m2) was calculated by normalizing CSA to patient height. Sarcopenia at L3 was defined as SMI ≤ 41.6 cm2/m2 for males and ≤ 32.0 cm2/m2 for females. Data analyses were performed to compare postoperative outcomes.

RESULTS: Of the 168 patients who met inclusion criteria, 47 patients (28.0%) were determined to have preoperative sarcopenia. The sarcopenic group was older (63 vs. 58 years, p = 0.017), had lower body mass index (BMI; 21.2 vs. 27.2, p < 0.001),< 0.001).< 0.001).< 0.01),< 0.01),< 0.01),< 0.01),< 0.05),< 0.05),< 0.05).< 0.001)

CONCLUSION: Sarcopenia was found to be a predictor of postoperative complications in H&N free flap reconstruction, signifying its value as a negative prognostic factor in surgical outcomes. This study reflects level of evidence IV.

PMID: 32088918 [PubMed - as supplied by publisher]

25 February 2020

13:16

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:16

In reply to this message

pubmed: caandvteortroorpul

Effectiveness of home-based preoperative pulmonary rehabilitation in COPD patients undergoing lung cancer resection.

Tumori. 2020 Feb 23;:300891619900808

Authors: Rispoli M, Salvi R, Cennamo A, Di Natale D, Natale G, Meoli I, Gioia MR, Esposito M, Nespoli MR, De Finis M, Buono S, Corcione A, Lavoretano S, Bianco A, Fiorelli A, Curcio C, Perrotta F

Prolonged trastuzumab therapy is the standard of care for women with metastatic HER2 positive (HER2+) breast cancer. There are limited data

Abstract

Prolonged trastuzumab therapy is the standard of care for women with metastatic HER2 positive (HER2+) breast cancer. There are limited data on the incidence of cardiotoxicity, its treatment implication, and cardiac care in these patients. We retrospectively identified consecutive women who received >12 months of trastuzumab treatment at Princess Margaret Cancer Centre (Toronto, ON) from 2007 to 2012 for metastatic HER2 positive breast cancer and followed them until death or August 2018. Patients were included if a pretherapy multigated acquisition scan and ≥2 subsequent follow-up scans were available. The Cardiac Review and Evaluation Committee Criteria were used to identify cardiotoxicity. Baseline characteristics and outcomes (final left ventricular ejection fraction, change in LVEF, trastuzumab interruption) were compared in patients with and without cardiotoxicity. Cardiac care and treatment received were recorded. Sixty patients (mean age 52 ± 10.4 years) were included. The median trastuzumab exposure was 37 cycles (interquartile range 23 to 56) over 28 months (interquartile range 19 to 49) and 48% received previous anthracycline therapy. The cumulative incidence of cardiotoxicity was 35% (95% CI 23 to 48) at 3 years. Patients who developed cardiotoxicity were more likely to receive third-line cancer treatments and had lower final LVEF than patients without (54.9% ± 6.3% vs 64% ± 4.9%, p <0.001).

PMID: 32087998 [PubMed - as supplied by publisher]

15:57

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

15:57

In reply to this message

pubmed: caandvteortroorpul

Impact of Sarcopenia on Outcomes of Autologous Head and Neck Free Tissue Reconstruction.

J Reconstr Microsurg. 2020 Feb 23;:

Authors: Alwani MM, Jones AJ, Novinger LJ, Pittelkow E, Bonetto A, Sim MW, Moore MG, Mantravadi AV

Doxorubicin (DOX) is widely used as an effective chemotherapy agent in cancer treatment. Cardiac toxicity in cancer treatment with DOX

Abstract

Doxorubicin (DOX) is widely used as an effective chemotherapy agent in cancer treatment. Cardiac toxicity in cancer treatment with DOX demand urgent attention and no effective treatment has been established for DOX-induced cardiomyopathy. It has been well documented that human amniotic membrane proteins (AMPs), extracted from amnion membrane (AM), have antioxidant, anti-apoptotic, and cytoprotective properties. Therefore, in this study, we aimed to investigate the protective effects of AMPs against cardiotoxicity induced by DOX in cultured rat cardiomyocyte cells (H9c2). DOX-induced cell injury was evaluated using multi-parametric assay including thiazolyl blue tetrazolium bromide (MTT), the release of lactic dehydrogenase (LDH), intracellular Ca2+ , reactive oxygen species (ROS) levels, cellular antioxidant status, mitochondrial membrane potential (ΔΨm), malondialdehyde (MDA), and NF-κB p65 DNA-binding activity. Moreover, expression profiling of apoptosis-related genes (P53, Bcl-2, and Bax) and Annexin V by flow cytometry were used for cell apoptosis detection. It was shown that AMPs pretreatment inhibited the cell toxicity induced by DOX. AMPs effectively attenuated the increased levels of LDH, Ca2+ , ROS, and MDA and also simultaneously elevated the ΔΨm and antioxidant status such as superoxide dismutase (SOD) and Catalase (CAT) in pretreated H9c2 cardiomyocytes. Besides, the activity of NF-kB p65 was reduced and the p53 and Bax protein levels were inhibited in these myocardial cells subjected to DOX. These findings provide the first evidence that AMPs potently suppressed DOX-induced toxicity in cardiomyocytes through inhibition of oxidative stress and apoptosis. Thus, AMPs can be a potential therapeutic agent against DOX cardiotoxicity.

PMID: 32086724 [PubMed - as supplied by publisher]

12:35

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:35

In reply to this message

pubmed: ctoall&ca or conall

Trastuzumab related cardiotoxicity in nonmetastatic breast cancer: A real-world scenario.

Ann Oncol. 2019 May;30 Suppl 3:iii69

Authors: Shrivastva S, Prasad SK, Chennamaneni R, Stalin B, Konatam ML, Gundeti S

PMID: 32084902 [PubMed - as supplied by publisher]

12:35

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:35

In reply to this message

pubmed: ctoall&ca or conall

Anti HER-2 therapies and left ventricular dysfunction: A prospective study.

Ann Oncol. 2019 May;30 Suppl 3:iii32

Authors: Daniele AJ, Gregorietti VE

PMID: 32084781 [PubMed - as supplied by publisher]

15:14

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

15:14

In reply to this message

pubmed: caandvteortroorpul

A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.

Lung Cancer. 2020 Jan 22;142:34-40

Authors: Alexander M, Pavlakis N, John T, O'Connell R, Kao S, Hughes BGM, Lee A, Hayes SA, Howell VM, Clarke SJ, Millward M, Burbury K, Solomon B, Itchins M

Abstract

OBJECTIVE: To analyze populational trends and perioperative complications following conservative surgery versus oophorectomy in women <50

DESIGN: Population-based retrospective observational study.

SETTING: Nationwide Inpatient Sample in the United States (2001-2015).

POPULATION: 89,177 ovarian torsions including 20,597 (23.1%) conservative surgeries and 68,580 (76.9%) oophorectomies.

METHODS: (i) trend analysis to assess utilization of conservative surgery over time, (ii) multivariable binary logistic regression to identify independent factors associated with conservative surgery, and (iii) inverse probability of treatment weighting with a generalized estimating equation to analyze perioperative complications.

MAIN OUTCOME MEASURES: trends, characteristics, and complications related to conservative surgery.

RESULTS: Performance of conservative surgery increased from 18.9% to 25.1% between 2001-2015 (32.8% relative increase, P=0.001) but decreased steadily after age 15 and sharply declined after age 35 (P<0.001).<0.001).<0.001)

CONCLUSION: There was an increasing utilization of conservative surgery for ovarian torsion in the United States in recent years. Our study suggests that conservative surgery for ovarian torsion may not be associated with increased perioperative complications.

PMID: 32086987 [PubMed - as supplied by publisher]

15:15

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

15:15

In reply to this message

pubmed: caandvteortroorpul

Safety and effectiveness of direct oral anticoagulants for venous thromboembolism in patients with active cancer: a retrospective study.

Ann Oncol. 2019 Jul;30 Suppl 4:iv45

Authors: Ogata M, Satake H, Ama Y, Hirabatake M, Ogata T, Yasui H, Hashida T

PMID: 32085168 [PubMed - as supplied by publisher]

15:15

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

15:15

In reply to this message

pubmed: caandvteortroorpul

Imaging-proven venous thromboembolism among breast cancer patients in a tertiary hospital in the Philippines from 2010-2015.

Ann Oncol. 2019 May;30 Suppl 3:iii61

Authors: Gerona ATB, Gorospe AE

PMID: 32084878 [PubMed - as supplied by publisher]

24 February 2020

13:10

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:10

In reply to this message

pubmed: ctoall&ca or conall

Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.

Am J Cardiol. 2020 Jan 27;:

Authors: Calvillo-Argüelles O, Abdel-Qadir H, Suntheralingam S, Michalowska M, Amir E, Thavendiranathan P

OBJECTIVES: This study aimed to describe the longitudinal thromboembolism (TE) risk relative to the natural history of disease and clinical

Abstract

OBJECTIVES: This study aimed to describe the longitudinal thromboembolism (TE) risk relative to the natural history of disease and clinical course of ROS1 rearranged non-small cell lung cancer (NSCLC).

MATERIALS AND METHODS: Cases of ROS1-rearranged NSCLC from six Australian hospitals were pooled and evaluated for incidence, timing, predictors and outcomes of venous or arterial TE, as well as objective response rate (ORR) to active therapy and overall survival (OS).

RESULTS: Of 42 patients recruited, 20 (48%) experienced TE; one (2%) arterial, 13 (31%) a pulmonary emboli (PE), and 12 (29%) a deep vein thrombosis. Among those with TE, six (30%) experienced multiple events, three as concurrent and three as recurrent diagnoses. The cumulative incidence of TE over time, adjusted for death as a competing risk factor, approached 50%. TE occurred prior to, during and post the peri-diagnostic period and occurred irrespective of treatment strategy. A thrombophilia was identified in n = 3/10 (30%) cases screened: in two factor V Leiden and in one anti-thrombin III (ATIII) deficiency. Median OS was 21.3 months in those with TE vs. 28.8 months in those without; hazard ratio 1.16 (95%CI 0.43-3.15). Respective ORR to first-line therapy with TE was 50% vs. 44% without TE in the chemotherapy arm and 67% vs. 50% in the targeted therapy arm.

CONCLUSION: In the rare cancer subtype, ROS1, these real-world data demonstrate sustained TE risk beyond the diagnostic period irrespective of therapeutic strategy. High incidence of PE, concurrent TE, and recurrent TE warrant validation in larger cohorts. Consideration of primary thromboprophylaxis in ROS1 populations is recommended.

PMID: 32087434 [PubMed - as supplied by publisher]

15:14

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

15:14

In reply to this message

pubmed: caandvteortroorpul

Conservative surgery for ovarian torsion in young women: perioperative complications and national trends.

BJOG. 2020 Feb 22;:

Authors: Mandelbaum RS, Smith MB, Violette CJ, Matsuzaki S, Matsushima K, Klar M, Roman LD, Paulson RJ, Matsuo K

There is increasing evidence that rates of atrial arrhythmias (AA), specifically atrial fibrillation and flutter are elevated in patients treated

Abstract

There is increasing evidence that rates of atrial arrhythmias (AA), specifically atrial fibrillation and flutter are elevated in patients treated with the tyrosine kinase inhibitor, ibrutinib; however, the exact risk of ibrutinib-associated AA is not definitively established. We conducted a retrospective study of 137 patients diagnosed with B-cell malignancies treated with ibrutinib compared with 106 patients treated with chemotherapy for the same cancers in order to quantify the rates and risk of AA in a "real-world" sample of cancer patients. Fisher's exact test was used to evaluate for any statistically significant differences between groups. Logistic regression was used to generate odds ratios, adjusting for potential confounders. Incidence of AA was 14% (n = 17) in ibrutinib-treated patients compared with 3% (n = 3) in patients treated with chemotherapy (p = 0.009). Ibrutinib-treated patients were significantly older (mean age 67 vs 63 years, p = 0.003); however, there were no other significant differences in baseline characteristics. Ibrutinib use, age, hypertension, and previous use of ACE inhibitors, angiotensin receptor blocker use, β blocker use, and aspirin use were independently associated with incident arrhythmias. In multivariable analysis, patients treated with ibrutinib were associated with a 5-fold increased risk of developing AA (odds ratio = 5.18, 95% confidence interval 1.42 to 18.89). In conclusion, the rates and risk of AA are higher in patients treated with ibrutinib compared with chemotherapy, and this study provides strong evidence that ibrutinib itself is an independent risk factor for the development of incident AA.

PMID: 31208701 [PubMed - indexed for MEDLINE]

20:15

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

20:15

In reply to this message

pubmed: ctoall&ca or conall

Comorbidities: Cardiovascular disease and breast cancer.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.nature.com-images-logo_nrcardio.gif Related Articles

Comorbidities: Cardiovascular disease and breast cancer.

Nat Rev Cardiol. 2018 03 13;15(4):200-202

Authors: Moey M, Moslehi J

PMID: 29532794 [PubMed - indexed for MEDLINE]

23 February 2020

12:35

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:35

In reply to this message

pubmed: ctoall&ca or conall

Human Amnion Membrane Proteins Prevent Doxorubicin-Induced Oxidative Stress Injury and Apoptosis in Rat H9c2 Cardiomyocytes.

Cardiovasc Toxicol. 2020 Feb 21;:

Authors: Faridvand Y, Haddadi P, Vahedian V, Nozari S, Nejabati HR, Pezeshkian M, Afrasiabi A, Safaie N, Jodati A, Nouri M

BACKGROUND: Treatment de-escalation in early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) has been attempted

Abstract

BACKGROUND: Treatment de-escalation in early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) has been attempted in order to decrease costs and toxicities. One of the strategies pursued is decreasing trastuzumab treatment duration, with mixed results thus far. Trastuzumab-associated cardiotoxicity, however, may be more frequent with 12 months of trastuzumab compared with shorter treatment lengths. Therefore, we have conducted a meta-analysis to address this question.

MATERIALS AND METHODS: A meta-analysis of trials testing 12 months of adjuvant trastuzumab versus shorter regimens, reporting cardiac outcomes in patients with HER2-positive BC was performed with the random effects model with inverse variance weighting.

RESULTS: Clinical cardiac dysfunction associated with 12 months of trastuzumab versus shorter trastuzumab regimens, including 11 250 patients, showed a pooled OR (pOR) of 1.90 (95% CI 1.37 to 2.64; p value <0.001;<0.001;<0.001;

CONCLUSIONS: Compared to shorter treatment durations, there is sufficient evidence that 12 months of trastuzumab yields higher odds for the occurrence of relevant cardiac events. An individual patient-level data meta-analysis is needed in order to provide adequate data on risk factors for cardiotoxicity.

PMID: 32079624 [PubMed - in process]

20:15

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

20:15

In reply to this message

pubmed: ctoall&ca or conall

Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif Related Articles

Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.

Am J Cardiol. 2019 08 15;124(4):539-544

Authors: Fradley MG, Gliksman M, Emole J, Viganego F, Rhea I, Welter-Frost A, Armanious M, Lee DH, Walko C, Shah B, Chavez JC, McLeod H, Pinilla-Ibarz J, Schabath MB

Each week, I record audio summaries for every paper in JACC, as well as an issue summary. Although this process is quite time-consuming, I have

Abstract

Each week, I record audio summaries for every paper in JACC, as well as an issue summary. Although this process is quite time-consuming, I have become familiar with every paper that we publish. Thus, I have personally selected the top 100 papers (both Original Investigations and Review Articles, and an occasional Editorial Comment) from the distinct specialties each year. In addition to my personal choices, I have included papers that have been the most accessed or downloaded on our websites, as well as those selected by the JACC Editorial Board members. In order to present the full breadth of this important research in a consumable fashion, we will present these abstracts in this issue of JACC, as well as most of the central illustrations, with the realization that a magnifying glass will be be needed for appropriate visualization. The highlights comprise the following sections: Basic & Translational Research, Cardiac Failure & Myocarditis, Cardiomyopathies/Congenital & Genetics, Cardio-Oncology, Coronary Disease & Interventions, Hypertension, Imaging, Metabolic & Lipid Disorders, Neurovascular Disease & Dementia, Promoting Health & Prevention, Rhythm Disorders & Thromboembolism, Valvular Heart Disease, and Vascular Medicine (1-100).

PMID: 32081288 [PubMed - in process]

20:14

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

20:14

In reply to this message

pubmed: ctoall&ca or conall

Targeting MDR-1 gene expression, BAX/BCL2, caspase-3 and Ki-67 by nano-encapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity.

Fundam Clin Pharmacol. 2020 Feb 21;:

Authors: El-Sisi AE, Sokkar SS, Ibrahim HA, Hamed MF, Abu-Risha SE

There is a great demand to introduce new approaches into cancer treatment field due to incidence increase of breast cancer all over the world.

Abstract

There is a great demand to introduce new approaches into cancer treatment field due to incidence increase of breast cancer all over the world. The current study was designed to evaluate the role of imatinib mesylate (IM) and/or hesperidin (HES) nanoparticles alone or in combination in enhancing the anti-cancer activity, and to investigate the ability of nanoencapsulation to reduce cardiotoxicity of IM in Solid Ehrlich Carcinoma (SEC)-bearing mice. IM and HES were loaded into PLGA (poly(lactic-co-glycolic acid) polymer. SEC was induced in female albino mice as a model for experimentally induced breast cancer. Mice were randomly divided into eight groups (n =10). On day 28 from tumor inoculation, mice were sacrificed and blood samples were collected in heparinized tubes for hematological studies, biochemical determination of lactate dehydrogenase (LDH) and glutamic oxaloacetic transaminase (SGOT) levels. In addition, tumor and cardiac tissues were utilized for histopathological examination as well as determination of MDR-1 gene expression. Immunohistochemical staining of BAX and BCL-2 was done. Nano IM and/or Nano HES treated groups showed a significant reduction in tumor volume, weight, hematological, cardiac markers and tumor MDR-1 gene down regulation compared to free conventional treated groups. In conclusion, the use of HES as an adjuvant therapy with IM could improve its cytotoxic effects and limit its cardiac toxicity. Furthermore, nano-encapsulation of IM and/or HES with PLGA polymer showed a remarkable anti-cancer activity.

PMID: 32080901 [PubMed - as supplied by publisher]

20:14

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

20:14

In reply to this message

pubmed: ctoall&ca or conall

Dedicated to cardio-oncology.

Eur Heart J. 2020 Feb 21;41(8):907-909

Authors: Zhang Y, Liu Y, Xia Y

PMID: 32080730 [PubMed - in process]

20:15

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

20:15

In reply to this message

pubmed: ctoall&ca or conall

Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors - a WHO pharmacovigilance database analysis.

Eur Respir J. 2020 Feb 20;:

Authors: Moey MYY, Gougis P, Goldschmidt V, Johnson DB, Lebrun-Vignes B, Moslehi J, Cadranel J, Salem JE

PMID: 32079644 [PubMed - as supplied by publisher]

20:15

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

20:15

In reply to this message

pubmed: ctoall&ca or conall

Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials.

ESMO Open. 2020 Feb;5(1):

Authors: Eiger D, Franzoi MA, Pondé N, Brandão M, de Angelis C, Schmitt Nogueira M, de Hemptinne Q, de Azambuja E

Doxorubicin (Dox) is an effective chemotherapeutic for a variety of pediatric malignancies. Unfortunately, Dox administration often results in a cumulative

Abstract

Doxorubicin (Dox) is an effective chemotherapeutic for a variety of pediatric malignancies. Unfortunately, Dox administration often results in a cumulative dose-dependent cardiotoxicity that manifests with marked oxidative stress leading to heart failure. Adjunct therapies are needed to mitigate Dox cardiotoxicity and enhance quality-of-life in pediatric cancer patients. Angiotensin-(1-7) [Ang-(1-7)] is an endogenous hormone with cardioprotective properties. This study investigated whether adjunct Ang-(1-7) attenuates cardiotoxicity resulting from exposure to Dox in male and female juvenile rats. Dox significantly reduced body mass and the addition of Ang-(1-7) had no effect. However, adjunct Ang-(1-7) prevented Dox-mediated diastolic dysfunction, including markers of decreased passive filling as measured by reduced early diastole mitral valve flow velocity peak (E) (p<0.05)<0.001)<0.001),<0.05),<0.001)<0.001),<0.05;<0.01)<0.05)

PMID: 32083974 [PubMed - as supplied by publisher]

20:14

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

20:14

In reply to this message

pubmed: ctoall&ca or conall

Editor-in-Chief's Top Picks From 2019.

J Am Coll Cardiol. 2020 Feb 25;75(7):776-834

Authors: Fuster V

zer

zer

ad2

zer

ad2

zer

Labels

Pages

Search This Blog

Translate

Pages

خلفيات وصور / wallpapers and pictures images / fond d'écran photos galerie / fondos de pantalla en i

Buscar este blog

12/8/23

Labels

Popular Posts

Popular Posts

Popular Posts

Popular Posts

Translate

Blog Archive

Blog Archive

Featured Post